Literature DB >> 2475705

Arterial and venous effects of serotonin in the forearm of healthy subjects are not age-related.

G J Blauw1, P van Brummelen, P C Chang, P Vermeij, P A van Zwieten.   

Abstract

The influence of age on the regional arterial and venous effects of serotonin (5-HT) was investigated in 13 young (aged 22-31 years) and seven older (aged 50-69 years) healthy volunteers. Single-dose infusions of 5-HT (1, 10, and 80 ng/kg/min) and of the 5-HT2 receptor antagonist ritanserin (50, 150, and 500 ng/kg/min) were administered into the brachial artery. Subsequently, the relative arterial and venous effects of the highest dose of 5-HT were investigated. Forearm blood flow (FBF) and maximum venous outflow (MVO) were measured by venous occlusion plethysmography. Heart rate (HR) and intraarterial (i.a.) blood pressure were recorded semicontinuously. In both age groups, 5-HT induced an initial transient arterial dilation, followed by a persistent increase in FBF for the doses of 1 and 10 ng/kg/min and a relative small decrease in FBF for the highest dose. In both age groups, the highest dose of 5-HT induced a similar large reduction in MVO (p less than 0.05 for both). The reduction in MVO was attenuated by ritanserin (500 ng/kg/min, p less than 0.05 for both groups). In the younger subjects, this dose of ritanserin also unmasked an arterial dilator effect of the highest dose of 5-HT (p less than 0.05). The single infusions of ritanserin did not influence FBF significantly in either study group. No significant differences were observed between the age groups. These results show that in the forearm of healthy subjects arterial and venous vascular responses to 5-HT were not age-related. In the arterial vascular bed, 5-HT acted predominantly as a vasodilator; at high doses, mainly venous vasoconstriction was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475705     DOI: 10.1097/00005344-198907000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Antihypertensive treatment with ketanserin shows no evidence of vascular serotonin2-receptor and alpha 1-adrenoceptor blockade.

Authors:  G J Blauw; C J Doorenbos; T A Bruning; P van Brummelen; P A van Zwieten
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.